Johnson & Johnson seals $30 billion Actelion deal
Bloomberg Johnson & Johnson agreed to buy Actelion Ltd. for $30 billion and spin off the Swiss drugmaker’s research and development operations, clinching its largest deal ever to become a leader in medicines for a rare type of high blood pressure. J&J, already the world’s biggest maker of health-care products, is fulfilling its goal of gaining a new drug ...
Read More »